Previous 10 | Next 10 |
AC Immune (ACIU) and its strategic partner Janssen Pharmaceuticals Johnson & Johnson (JNJ) have expanded the ongoing Phase 1b/2a clinical trial of an anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease ((AD)).The trial expa...
Previous interim results showing strong safety and potent immunogenicity support trial expansion and advancement of ACI-35.030 into Phase 2b/3 Alternative vaccine candidate also advances to second highest dose group based on encouraging interim results LAUSANNE, Switzerlan...
AC Immune (ACIU): Q1 GAAP EPS of -CFH0.23.Cash and cash equivalents of CHF151.1MFY2021 guidance: Total cash burn to range between CHF 65M- 75M.Press Release For further details see: AC Immune reports Q1 results; outlook
Reported potent interim immunogenicity results for anti-pTau Alzheimer’s vaccine in ongoing Phase 1b/2a study, which support further development into Phase 2/3 Initiated first-in-human clinical study for next-generation alpha-synuclein PET diagnostic with results expected in ...
Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investments for several clinical-stage companies as a Partner at Sofinnova Investments LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a cli...
LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss the unique benefits of the Company’s innovati...
Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases Webinar will take place on Wednesday, March 31, 2020 at 10:00 AM ET LAUSANNE, Switzerland, March 26, 2021 (GLOBE NEWSWIRE) -- A...
ACIU is developing drugs for Alzheimer's disease. They have some cash and a lot of partnerships. However, amyloid plaque removal is not a novel hypothesis. For further details see: AC Immune: Old Theory, New Company
AC Immune (ACIU): FY Non-GAAP EPS of -CHF0.79 misses by CHF0.02; GAAP EPS of -CHF0.86 misses by CHF0.04.Revenue of CHF15.4M (-86.1% Y/Y) misses by CHF0.37M.FY2021 guidance: Total cash burn to range between CHF 65M-75M.Press Release For further details see: AC Immune EPS misses by ...
Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3 Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b safety and immunogenicity results in Down syndrome; further interim res...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...